三生制药
3SBIO INC.

2022 Annual Results Presentation

21 March, 2023

Disclaimer

This document has been prepared by 3SBio Inc. (the "Company") solely for selected recipients for information purposes only.

You must read the terms, conditions, limitations, notifications, restrictions, acknowledgments and representations in the following (collectively, the "Terms") before reading or making any other use of this document. In accepting the delivery of, reading or making any other use of this document, you acknowledge and agree to be bound by the Terms, and you agree to maintain absolute confidentiality regarding the information disclosed in this document in a manner consistent with the Terms. If you do not accept any of the Terms, in whole or in part, please immediately return this document to the Company.

These materials, and any further information made available to you, are highly confidential and are being given solely for your information. These materials, and any further information made available to you, form part of the proprietary information of the Company and may not be copied, reproduced, redistributed or passed on, directly or indirectly, to any other person (whether within or outside your organization/firm) or published or otherwise disclosed, in whole or in part, in any manner and for any purpose without the prior written consent from the Company. Any forwarding, distribution or reproduction of this document, in whole or in part, is unauthorized.

The information used in preparing this document has not been independently verified and has not been reviewed by any regulatory authority in any jurisdiction. This document does not purport to provide a complete description of the matters to which it relates. No representation, warranty or undertaking, express or implied, is or will be made or given by, and no responsibility or liability is or will be accepted by, any person (for the avoidance of doubt, including but not limited to, the Company and its affiliates, controlling persons, shareholders, directors, officers, partners, employees, agents, representatives or advisers of any of the foregoing), with respect to the accuracy, reliability, correctness, fairness or completeness of this document or its contents or any oral or written communication in connection with this document. In addition, any analyses included herein are not and do not purport to be complete or comprehensive and are not and do not purport to be appraisals of the assets, stock or business of the Company or any of its holding companies, subsidiaries or other affiliates. Even when these materials contain a form of appraisal, it should be considered as preliminary, suitable only for the purpose described herein, subject to assumptions and not be disclosed or otherwise used without the prior written consent of the Company. The information in this document does not take into account the effects of a possible transaction or certain transactions which may have significant valuation and other effects. Nothing contained in this document is, or shall be, relied upon as a promise or representation as to the future or as a representation or warranty otherwise.

Nothing in this document constitutes or forms part of, or should be construed as constituting or forming part of, any regulatory, valuation, legal, tax, accounting, investment, or other advice. Nothing in this document constitutes or forms part of, or should be construed as constituting or forming part of, any recommendation, solicitation, offer or commitment to purchase, sell, subscribe for or underwrite any securities by any party, or to extend any credit or provide any insurance to you or to enter into any transaction, nor shall there be any sale of securities or other transaction in any jurisdiction in which such sale or transaction would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. Unless otherwise agreed in writing, any third party from whom you receive this document is not acting as your financial adviser or fiduciary. Before you enter into any transaction, you should ensure that you fully understand the potential risks and rewards of that transaction and you should consult with such advisers as you deem necessary to assist you in making these determinations, including, but not limited to, your accountants, investment advisors and legal and/or tax experts. None of the Company and its affiliates, controlling persons, shareholders, directors, officers, partners, employees, agents, representatives or advisers of any of the foregoing shall have any liability (in negligence or otherwise) in respect of the use of, or reliance upon, the information contained herein by you or any person to whom the information herein is disclosed.

The contents of this document are subject to corrections or changes at any time without further notice. The information contained in these materials also contains certain forward-looking statements regarding the Company's intent, plans, beliefs, strategies, and growth prospects as well as the projected growth of China's economy and the pharmaceutical industry, which are based on various assumptions and subject to risks and uncertainties. In light of these assumptions, risks, and uncertainties, the future facts, events and circumstances described in these materials may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. The forward-looking statements are not guarantees of future performance. Each of the Company and its and its affiliates, controlling persons, shareholders, directors, officers, partners, employees, agents, representatives or advisers of any of the foregoing assumes no obligation to (1) provide access to any additional information, (2) correct any mistakes or inaccuracies in this document, or (3) update or otherwise revise this document, for any reason whatsoever, including without limitation to reflect new information, events or circumstances that arise, occur or become known after the date of this document.

By receiving or reading this document, you acknowledge and represent to the Company and its affiliates, controlling persons, shareholders, directors, officers, partners, employees, agents, representatives or advisors that (1) you are a "professional investor" as defined in the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) and the rules made thereunder, have the knowledge and experience in financial and business matters, and are capable of evaluating the merits and risks of and conducting your own assessment of the Company and its shares, (2) you are a person into whose possession this document may lawfully be delivered in accordance with the laws of the jurisdiction in which you are located, and (3) you have conducted and will conduct your own investigation with respect to the Company and its shares and have obtained or will obtain your own independent advice relating to the investment in the shares of the Company, and, if located in the United States, are either a "qualified institutional buyer" or an institutional "accredited investor" as defined in the U.S. Securities Act of 1933, as amended, and the regulations enacted thereunder (the "U.S. Securities Act").

No information set out in this document will form the basis of or be relied upon in connection with any contract, commitment or investment decision. Any prospective investor will be required to acknowledge in any purchase contract that it has not relied on, or been induced to enter into such agreement by, any representation or warranty, save as expressly set out in such agreement. This document does not constitute, in whole or in part, an offer or invitation for the sale, purchase or subscription of any security. Any such offer or invitation will be made solely through a prospectus or offering circular in compliance with all applicable laws and any decision to purchase or subscribe for any security should be made solely on the basis of the information contained in such prospectus or offering circular issued in connection with such offer or invitation.

This document contains no information or material which may result in it being deemed (1) to be a prospectus within the meaning of the U.S. Securities Act; (2) to be a prospectus within the meaning of section 2(1) of the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Chapter 32 of the Laws of Hong Kong), or an advertisement in relation to a prospectus or proposed prospectus or extract from or abridged version of a prospectus within the meaning of section 38B of the Companies (Winding Up and Miscellaneous Provisions) Ordinance or an advertisement, invitation or document containing an advertisement or invitation falling within the meaning of section 103 of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) or (3) to have effected an offer to the public in the United States, Hong Kong or anywhere else without compliance with all applicable laws and regulations or being able to invoke any exemption available under all applicable laws and regulations and is subject to material change without notice. The distribution of this document may be restricted by law, and persons into whose possession this document comes should inform themselves of, and observe, any such restrictions. Any failure to comply with these restrictions may constitute a violation of the applicable securities laws. The Company does not intend to conduct any public offering of securities in the United States, Hong Kong or anywhere else.

Agenda

01 2022 Highlights

02 Business Overview

03 R&D

04 Financial Review

05 Q&A

01 2022 Highlights

Chairman, Director & CEO
Dr. Jing LOU

2022 Financial Highlights

Revenue



- YoY +7.5%
- 5 years CAGR: 10.6%

NI Attributable to Parent



- YoY +16.0%
- 5 years CAGR: 10.7%

Norm NI Attributable to Parent



- YoY +25.2%
- 5 years CAGR 16.7%

EPS

- YoY +20.0%



2022 Highlights

Biopharmaceuticals


TPIAO®


EPIAO® SEPO®


Yisaipu®


Cipterbin®

Hair Healthiness


Mandi


Mandi white bottle


Mandi Pro


Mandi Shampoo

CDMO

R&D


YSP Pre-filled Injection


Remitch


Mandi Foam

4
Chemicals submitted ANDA

Core product revenue
5.2 Bn RMB

YoY +**3.0%**

Core product revenue
907 Mn RMB

YoY +**46.5%**

External order revenue
166 Mn RMB

YoY +**49.6%**

8 NDA/ANDA submissions accepted for review

31 product pipelines

2022 Key Milestones

R&D

Advanced Key Candidates to the Late Clinical Stage

Jun. 2022 Phase Ib clinical trial of TPIAO in CLDT completed all subjects enrollment

Aug-Dec. 2022 Phase Ib study of anti-IL-1β mAb (613) in AG arthritis completed enrollment, anti-IL-5 mAb (610) in eosinophil asthma started phase II trial, anti-IL-4R mAb (611) in AD completed phase Ia in U.S, phase II enrollment ready to complete

Nov. 2022 TPIAO in pediatric ITP NDA was accepted for review

Nov. 2022 Phase Ⅱ clinical study of anti-IL-17A mAb (608) in PsO achieved the primary endpoint, phase Ⅲ trial completed enrollment

Hair Healthiness

Top Brand in Hair Healthiness

Jan. 2022 5% Mandi Foam NDA was accepted for review

Jun. 2022 Licensed in exclusive right to develop and commercialize cream Winlevi® to treat acne in Greater China and the right of first refusal of Breezula® solution to treat alopecia from Cosmo

Jun. 2022 Mandi “618” E-commercial sales revenue set a new record

Nov. 2022 Mandi ranked first among chemical brands in Chinese online drugstore in 2022H1, and won the drug champion Ali & JD platform during 2022 Double 11

Biopharmaceuticals

Core Biopharmaceuticals Recognized by More Guidelines

Apr. 2022 Cipterbin was the primary recommendation for anti-HER2 patients in Treatment Guidelines for Breast Cancer (2022)

Apr. 2022 TPIAO was recommended as the first-tier CTIT treatment drug in Guidelines for CSCO Cancer Therapy Induced Thrombocytopenia (2022)

Apr. 2022 “Practice Guidelines for Cancer Induced Anemia 2022” added 36000IU for primary recommendations

CDMO

Improving Client Service Capabilities

Jun. 2022 Advanced our clients successfully to submit BLA

Oct. 2022 Guangdong Sunshine obtained Drug Manufacturing License

Dec. 2022 Shenyang Desen obtained Drug Manufacturing License

MSCI ESG Rating: Upgraded to AA

Exceeding **88%**

Biotech companies worldwide

MISSION

Making innovative biopharmaceuticals within the reach

VISION

Based in China, the Group aspires to be a leading global biopharmaceutical company

VALUES

Innovation, Quality, Win-win cooperation

PHILOSOPHYS

Cherish life, Caring for life, Create life

Social Responsibility

Social Contribution

TPIAO Charity Donation
YSP Charity Donation
YSP Initiative Price Cut

Environment

Continuous energy conservation and emission reduction

Employee Development

System on Training Retention and Promotion



02 Business Overview

Biopharmaceuticals

TPIAO- Exclusive Commercialized rhTPO Product

Revenue of TPIAO, 2022

1 Top 1 Market Share

65% [1] market share in term of sales, the largest market share in platelet therapy area



1.Data source： IQVIA Jan-Dec, 2022， Total market volume includes TPO, interleukin-11 and Eltrombopag

TPIAO- Clear Mechanism Brought Great Advantages

Faster Acting, Higher Safety

Structure kept high consistent with endogenous TPO (eTPO)



- ✓ Highly consistent amino acid sequence
- ✓ Full and close galactosylated modification
- ✓ The same mechanism

700+ research articles, appeared in international academic forums repeatedly

Differential Signaling Transduction of TPO VS Romiplostim and Eltrombopag

- TPIAO combines extracellular C-MPL receptor, **simultaneously activates** JAK-STAT, MAPK, PI3K-AKT channels
- **Enhanced** signal transduction compared with micro-molecule drugs and Romiplostim





TPIAO- Sustainably Expand Cancer Induced TCP Market

Cancer Therapy Induced Thrombocytopenia (CTIT)

Refers to cancer treatment Induced Thrombocytopenia, not only including chemotherapy-induced Thrombocytopenia (CIT) , but also including radiotherapy, targeting therapy and immunotherapy induced thrombocytopenia [1]



Chemotherapy TCP Patients

1+ Mn patients, main indication covered by cancer TCP, continuous grassroots work



Radiotherapy TCP Patients

300+ K patients, if PLT < $75*10^9$, the drop-off rate of treatment would nearly reach 50%

Surgery TCP Patients

200+ K patients, PLT of large wound surgery must exceed $100*10^9$

Indication	R&D Progress
Pediatric ITP	NDA accepted for review
CLDT	Phase III started, cover liver diseases patients
First aid of bone marrow acute radiation syndrome	Animal models verify efficacy, as the first aid drug for bone marrow acute radiation syndrome, single large dose medication of TPIAO recommended in “Diagnosis of acute radiation sickness from occupational external exposure”
Muti- subjects development	AA, HSCT homing, GSDMD TCP etc.

1. “Guidelines for CSCO Cancer Therapy Induced Thrombocytopenia (2022)”

EPIAO & SEPO- Recombinant Human Erythropoietin

Revenue of rhEPO, 2022

RMB Mn

1

TOP 1 Market Share

Two brands dominate **44.5%** market share, Top 1 in EPO market



rhEPO- Sustained Growth Driven by Demand

Guideline recommendations increase, Treatment barriers removed, Clinical demand for EPO rise

36% Dialysis anemia penetration rate[1]

10% CIA penetration rate

- Renal anemia treatment QC standards for hemoglobin enhanced[2], the demand for EPO further increased
- EPO was added in various treatment guidelines[3] for CIA
- Diagnosis and treatment resumed, suppressed demand such as surgery and medication rebounded
- 800K+ patients, 10% annual growth rate, highly cost-effective drug in CKD anemia treatment

1.Data source: CNRDS 2020
2.NHC " 2021 Document for Improvement of Quality Control ([2021] no.51) "
3.Data source:on the 2018 National Essential Drug List, rhEPO covers 2000IU, 3000IU and 10000IU

Yisaipu- Explore to Reform

Revenue of Yisaipu, 2022

RMB Mn



The first biopharmaceutical for the treatment of chronic disease

18 years of clinical application experience in Chinese patients

Demand rebounds to growth

The demand for treatment of chronic diseases has returned to normal

Develop new formulation

Pre-filled injection may be launch in March 2023; sets with the injection have been launched

Explore new collaborations

Collaborate with TCM rheumatism system, based on the heavy evidence of combined therapy to seek new channels of growth

Persistent grass-roots work

Advance NEDL entry, promote rural revitalization projects, improve treatment level of grassroots, consolidate first-mover advantages

The first TNF-α inhibitor commercialized in China | Clinical experience surpass 18 years | Benefited over 100K patients in total | Trained 15012 staffs from fixed-point medical institutions | Covered 3700+ hospitals, including 900+ county-level hospitals

Cipterbin- Enter High-speed Growing Period

Revenue of Cipterbin, 2022



Guideline	Release Subject	Release Time	Recommendation
Treatment Guidelines for Breast Cancer (2022)	CSCO	2022	Advanced breast cancer first-line treatment recommendations
2022 NRDL	NHC	2023	Remove the limitation of combination with Vinorelbine

	2021	2022
Medical Institutions	590	1300
Total Patients	3000	10000
Monthly New Patients	200	500
Per Capita DOT	2 cycles DOT[1]	~7 cycles DOT

1. DOT（Duration of Treatment） Cipterbin lasts for 21 days

Hair Healthiness

Mandi- Effective & Reliable Hair Product

Revenue of Mandi, 2022

1 **Top 1 Market Share**

71.7% Market Share, secured top 1 minoxidil 1



1. Data source：CPA

Mandi- 3 Channels Propel Sales Increase

Hospital

14% of revenue, **2%** YOY

- Academic recognition continues to improve, recommendations of the highest level in female AGA guidelines
- Layout privately-operated medical institutions, expand cooperations with chains

Retail Pharmacy

25% of revenue, **65%** YOY

- 100K Pharmacy, covered 90% of Top Chains

国大药房 GuoDa Pharmacy
益丰大药房 Yifeng Pharmacy
大参林 DA SHEN LIN
北京同仁堂
老百姓大药房 LBX PHARMACY
海王星辰 NEP-STAR DRUG STORE

E-commerce

60% of revenue, **58%** YOY

- Annually reached 20 million plus people, 3 million plus customers
- New customer rate ~70%, per customer transaction 200+ rmb
- Female customer rate climbed continually

Platform		Rank	"Double 11" achievement
天猫	Tmall	1	Champion of OTC hair loss drug
京东	JD	1	No.1 of self-operated OTC skin drug
京东大药房	JD drugstore	1	No.1 item sold in drugstore

Mandi- Build Abundant Product Matrix



01 Mandi

60/90mL Male monthly course

02 Mandi white bottle

30mL Female monthly course, convenient and certain amount controllable

03 Mandi foam

Upcoming soon, fill hair-loss market for sensitive hair skin population

04 Mandi Pro (portable version)

10mL, Equipped with diverse brushes, more portable to meet diverse travel demand

05 Mandi comb

Laser massage & drug application & hair care integrated intelligent tool

06 Mandi shampoo

Extend to scenes of life in hair healthcare

CDMO

CDMO- Domestic Pioneer of CDMO

Revenue of CDMO, 2022

RMB Mn

YOY：49.6%

Formulations	Biopharmaceuticals	GCT	Biopharmaceutical




Sirton Pharmaceuticals　SIGO 晟国医药　广东三生 Guangdong Sunshine　德生生物 Desen Biologics

53% yoy
Revenue from overseas subsidiary

43% yoy
Revenue from domestic subsidiary

1
Commercialized product

100Mn+
Backlogs

76 KL capacities come into use for commercialized orders

CDMO- Advancing Construction

12Mn vias formulation gradually operated after Q4 2022, fourfold expansion after full operation

Powder- injection/ Freeze-dried powder- Injection

Pre-filled Injection

Vial

Stage I **2000L** disposable capacity and **40Mn** vias formulation completed; Stage II affinity resin and culture medium started construction

Biopharmaceuticals

Formulations

Culture medium

Affinity chromatography filling

Sirton

Sunshine, Guangdong

Desen, Shenyang

SIGO, Shanghai

Production certificate obtained in Sep. 2022; 1st contract targeted in US market has been signed

Biopharmaceuticals

GCT

Formulations

3500L disposable capacity, Est. completed in Q2 2023

Biopharmaceuticals

Formulations

03 R&D

R&D Pipeline



4
Pre-clinical

4
IND& phase I

8
Phase II

10
Phase III &NDA

5
BE &ANDA

- Small molecule drugs
- Antibody-drugs
- Other drugs

R&D Outlook- Upcoming Commercialization Boom



8 new products are coming to the market from **2023**

Key Candidates: SSS06 (Long-acting rhEPO)

Phase II clinical trial data indicate safety and efficacy

- 2nd-generation EPO， extend half -life for **2 weeks** dosing intervals, match treatment cycles of chemotherapy patients
- Phase II data showed that both dose groups were safe and effective；the changes in hemoglobin (Hb) after treatment were similar to the existing EPO
- ranks **NO.2** in China，Phase III enrollment completed

2024
Est. NDA

rhEPO VS SSS06 clinical efficacy data:

	rhEPO (Screening Dose)	**rESA QW** (0.5ug/kg)	**rESA QOW** (1.0ug/kg)
Mean baseline Hb (g/L)	110.70	110.1	**112.9**
Mean Hb during evaluation (g/L)	108.9	106.5	**107.7**
Primary Efficacy Endpoint			
Mean Change from baseline in mean Hb during the evaluation period (g/L)	-1.8	-3.7	**-5.1**
Adjusted mean change from baseline in mean Hb during the evaluation period (g/L)	-6.5	-8.3	**-8.2**
Mean difference (95% CI)		1.8(-1.8, 5.4)	**1.6(-2.1, 5.4)**

Key Candidates: Anti-IL17A mAb (608)

Phase II data shows specific efficacy in PsO

Week 12 Data shows the efficacy of 608 at different doses is much better than placebo group & marketed products, indicating Best-In-Class Potential

	608 Group A（n=28）	608 Group B (n=31)	608 Group C (n=35)	Placebo (n=11)	Secukinumab 300mg (W0~W4 QW) + Q4W
PASI 75	96.4%	93.5%	100.0%	9.1%	80.6%
PASI 90	92.9%	83.9%	91.4%	0.0%	57.2%
PASI 100	46.4%	48.4%	57.1%	0.0%	33.6%
sPGA 0/1	89.3%	83.9%	91.4%	9.1%	67.9%
PASI 75 +sPGA 0/1	89.3%	83.9%	91.4%	9.1%	/
PASI 90 +sPGA 0/1	89.3%	80.6%	91.4%	0	/

- Progress ranks **NO.3** in China

2024
Est. NDA

Week 12 primary endpoint data of 608, Secukinumab, Ixekizumab in PsO patients



注：T=Trial drug, P=Placebo

1. 608 Group A representative：160mg LD(loading dose)+80mg Q2W，608 Group B representative：160mg Q2W；**608 Group C representative**：160mg Q4W
2. PASI75, PASI90, PASI100 refers to PASI improved ≥75%, ≥90% and ≥100% higher than the baseline respectively
3. sPGA 0/1 refers to sPGA 0 score or 1 score, and declines ≥2 scores relative to the baseline; sPGA 0 refers to psoriasis area fully or nearly fully eliminated

Key Candidates: Anti-IL1β mAb (613)

Effectively Relieved Pains in Acute Gout Arthritis

- **Data from phase Ib trial in AG arthritis shows the VAS scores of 613 in different doses are improved significantly relative to the baseline**

	100 mg (N=10)	200 mg (N=10)	300 mg (N=10)
Baseline (%)	66.90 (13.195)	62.10 (10.311)	60.70 (13.475)
6H changes relative to the baseline after dose （%）	-9.67 (11.941)	-18.93 (13.510)	-14.34 (17.445)
24H changes relative to the baseline after dose （%）	-38.43 (34.236)	-45.20 (16.921)	-29.15 (29.012)
72H changes relative to the baseline after dose （%）	**-56.91 (42.359)**	**-71.77 (27.254)**	**-62.50 (30.287)**
D7 changes relative to the baseline after dose （%）	-82.12 (20.480)	-78.96 (20.279)	-74.77 (16.228)
D14 changes relative to the baseline after dose （%）	-85.18 (19.638)	-89.37 (12.249)	-91.96 (11.265)
D28 changes relative to the baseline after dose （%）	**-85.49 (30.870)**	**-93.48 (9.202)**	**-90.85 (15.645)**

- Progress ranks NO.2 in China： Phase II in AG arthritis in recruitment; Phase I in Periodic Fever Syndrome (PFS) and systemic juvenile idiopathic arthritis (sJIA) completed

2025
Est. NDA

VAS pain scores of target joint declined similar to Canakinumab



Key Candidates: Anti-IL4R mAb (611)

Phase Ib Data shows rapid response rate of 611 in severe AD patients

- The data from week 16 shows 611 takes effect in moderate-to-severe AD patients after 2 weeks doses
- **Rapid response rate, long-lasting effect**

	611 (NCT05641558)			
Week 16 effect results	300+150 QW (n=6)	600+300 Q2W (n=4) *	600+300 QW (n=6)	Placebo (n=5)
EASI-75	83.3	50.0	66.7	0.0

- The response rate of 611 trends to be higher than Dupilumab
- Progress ranks **NO.3** in China

2026
Est. NDA



Key Candidates: Anti-IL5 mAb (610)

Significantly Improve the pulmonary function of severe asthma patients

- Progress ranks **NO.1** in China

Company	Code	Indication
Sunshine Guojian	**SSGJ-610**	**Phase II in eosinophil asthma is in recruitment**
Hengrui	SHR-1703	Phase II in eosinophil asthma in recruitment; phase I in asthma in recruitment; phase I in bronchial asthma completed recruitment
Bio-Thera	Mepolizumab-BAT 2606	Phase I in chronic rhinosinusitis with polyposis completed recruitment

- Phase II trial in severe eosinophil asthma patients in recruitment

2026
Est. NDA

The analysis of phase Ib blinding clinical trial shows FEV1 is enhanced



Three Bispecific Antibody Platforms



- Form Quadrivalent BsAb with symmetric structure of two same heavy chains and four same light chains
- Stable physicochemical properties, druggability rivals to mAb
- Developed over 8 double targets BsAb

CLF2 (common light chain Linear-Fabs-IgG) BsAb Platform



- Support personalized design and multivalent BsAb & trispecific Ab production
- Stable scFv, Linker design avoid mispairing, stability and half-life similar to mAb
- Bacillus coli produce protein-toxin molecule structure, high penetration rate, high drug effect, substantially lower cost

MAP (Multi-directional Association Platform) BsAb Platform



- VHH/ IgSF unique BsAb platform based on Nanobody
- Symmetric structure, simple purified technology, expression and stability are equal with mAb

VRD-Body (Variable Regions Derivatives-Body) BsAb Platform

Key Candidates- Remitch

Remitch (Narfuraphine hydrochloride orally disintegrating tablets)

First-line Drugs for Liver& Kidney Disease Pruritus in Japan Guidelines

- Uremic pruritus (UP) -2009
- Chronic Liver Disease Pruritus(CLD-aP) -2015
- Peritoneal dialysis Pruritus -2017

Kappa-opioid receptor agonist, avoid respiratory depression, constipation and addiction

First-to-market domestic drug targeting hemodialysis pruritus patients

2018 Induced in

2019 IND approved

2021 Bridging trial succeeded

2022 NDA submission accepted for review

Exclusive product，Focus on Millions of Nephrology Patients' Clinical Demands

Irregular diagnosis and treat 01
Lack treatment guidelines, patient do not test, diagnose, treat correctly

Poor curative effect 02
Current treatment for pruritus do not consistent and adequate

Blank indications 03
No NMPA approved treatment, current drugs are used for off-label indications

Large side effects 04
Itch lead to drug abuse, co-infection, cardiovascular events etc.; addicted to opioid

Low quality of survival 05
60% of sleep disorders patients; possibility of depression doubled; death rate +24%

Key Candidates- Remitch

1

First and Only Symptomatic Drug

Become the first and only domestic drug in dialysis pruritus after approved, resolve problems such as respiratory depression, constipation and addiction brought by traditional opioids

Dialysis Pruritus

42%



Targeted Patients

>300k

- **80%** domestic millions of dialysis patients suffered from different degrees of pruritus
- About **42%** moderate-to-severe skin itching can not be effectively alleviated

Liver Disease related Pruritus

57%



Targeted Patients

>1Mn

- The incidence of pruritus ranges from 5% to 70% in different types of liver diseases
- Current treatment are not effective to over **57%** liver disease pruritus



International Cooperation- License in

Clascoterone (WS204)

1st in Class AR target drug to treat acne

- In July 2022, 3SBio Partnered with Cosmo and licensed in the exclusive right of Winlevi® (clascoterone cream 1%) to treat acne in Greater China

Winlevi® (clascoterone) cream 1%

- And the first refusal right of Breezula® (clascoterone solution 7.5%) for alopecia treatment (July 2022)

1st

First new mechanism of action in acne approved by the FDA in 40 years

- Winlevi® is the first marketed **external topical androgen receptor inhibitor** developed by Cosmo for the topical treatment of acne in patients 12 years and older, and was approved by FDA in November 2021[1].

450K

The most prescribed branded topical acne drug in the US

- Winlevi®is already the **most** prescribed branded topical acne drug in the US . By the end of 2022, over 10,000 US physicians have prescribed Winlevi ®, generated over 450K prescriptions [2]

Innovative product to exploit the huge potential of Chinese market

of Chinese are suffering from acne in various degrees[2]

young people aging from 10 to 25 years old suffered from acne

of patients are left acne scars, causing physical and psychological damage to them

Winlevi® Male Subjects		Winlevi® Female Subjects	
			
BASELINE	WEEK 12	BASELINE	WEEK 12

1：www.winlevi.com
2：www.cosmopharma.com, Bloomberg

International Cooperation- License out

SSS11 Pegsiticase

PEG-modified Recombinant Uricase

- Produced by C. utillis, with higher activity than other uricase in the physiological PH range of human body

609A

Recombinant Humanized anti-PD-1 mAb

- Global development and commercialization rights of 609A for Syncrovax™ (specific therapy) licensed-out to Syncromune Inc. Total deal size is more than 1 billion USD.

Cipterbin

Inetetamab

- Global development and commercialization rights of using Cipterbin as a part of ADC(s) was out-licensed to Kelingyuan, with total deal amount at more than 1billion RMB.

2014	Jul 2020	Nov 2020	2022	2023 Est.
Cooperation Achieved	**Cooperation Expanded**	**Milestone Reached**	**CDMO service**	**BLA to FDA**
3SBio authorized the right (excluding greater China and Japan) of Pegsiticase to **Selecta** for the combination therapy SEL-212, which consists of Pegsiticase and Selecta's proprietary ImmTOR® immune tolerance platform	**Sobi** reached license agreement with Selecta in charge of development, registration and commercialization of SEL-212, while **Selecta** conducted phase III clinical trial on behalf of Sobi.	In the U.S., Selecta has commenced the **phase III** clinical program of the combination therapy SEL-212 for treatment of chronic refractory gout, trigger a milestone payment of **4 million USD** to 3SBio	Provide Selecta/Sobi with Uricase drug substance **21** batches , preparing drug substance supply for **PPQ** batch	3SBio will receive **milestone payment**, continuous **royalty fee** and **CDMO revenue** for supply drug substance

三生制药 3SBIO INC. Selecta Biosciences sobi

04 Financial Review

Financial Analysis

Revenue

RMB Bn



Gross Profit

RMB Bn



NI Attributable to Parent

RMB Bn



NORM NI Attributable to Parent

RMB Bn



Expense Management

Selling and Distribution Expenses

RMB Bn



S&D Ratio	36.9%	36.7%	36.1%	36.4%	37.6%

R&D Costs

RMB Mn



R&D Ratio	7.9%	9.9%	10.6%	11.8%	10.1%

Administrative Expenses

RMB Mn



A&E Ratio	6.9%	12.7%	8.1%	5.8%	5.6%

Total Assets & Debt

Total Assets



Net Assets



Debt Asset Ratio



Sublime CF Condition, Sufficient FCF

OCF

RMB Bn



Cash Equivalents (Financing Proceeds Included)

RMB Bn



Extremely Attractive Earnings

EPS



ROE



Sustain Robust Growth, Repay Shareholders



Net Income attributable to parent
5 years of CAGR 10.7%

Robust Performance

Deliver sustainable growth to shareholders

SUSTAINABLE

TPIAO

Exclusive Product

Successful NRDL renewal, promising growth potential

EXCLUSIVE

Cipterbin

First-line Drug

Improve clinical recognition, break growth bottlenecks

PROFESSIONAL

Mandi

Top 1 Brand

Advanced penetration rate, continuous fast growth, expansion in dermatology

UNIQUE

R&D

New Launch

10 new products[1] are coming to the market since 2023

PROMISING

Dividends
Robust growth supports **sustainable** dividend policy

Shares Repurchase
Repurchased **5%** of shares, relieved financial pressure of shareholders

CB Redeem
Redeemed CB of **€30 mn**, enhanced the CB's security, improved confidence of investors

Shares Cancel
Cancelled **3.4%** of shares, cut short share capital and enhanced EPS, improved stock value and repaid shareholders

1: Est. include Remitch, YSP pre-filled injection, Mandi foam, TPIAO in pediatric ITP, Tofacitinib, Sevelamer carbonate, Apremilast, Cinacalcet hydrochloride, Eltrombobag, anti-IL17A mAb etc.

05 Q&A

THANKS

3SBio Inc. (1530.HK)
Investor Relations
ir@3sbio.com

珍 爱 生 命 · 关 注 生 存 · 创 造 生 活

CHERISH LIFE CARE FOR LIFE CREATE LIFE